Key Points
The CEO of Mineralys reported selling 10,700 shares for $291,468 on July 13, 2026.
The transaction reduced direct common stock holdings by 2%, as reported in the Form 4.
The sale was executed pursuant to a Rule 10b5-1 trading plan established on January 28, 2025.
Chief Executive Officer Jon Congleton reported a sale of 10,700 shares of Mineralys Therapeutics, Inc. (NASDAQ:MLYS) on July 13, 2026, according to an SEC Form 4 filing.
Transaction summary
| Metric | Value |
|---|---|
| Shares sold (directly held) | 10,700 |
| Transaction value | $291,468 |
| Post-transaction shares (directly held) | 603,621 |
| Post-transaction value | $16.65 million |
Transaction value based on SEC Form 4 weighted average sale price ($27.24); post-transaction value based on July 13, 2026 market close ($27.59).
Key questions
- How does this transaction align with the insider's total equity position?
Following the sale of 10,700 shares, Congleton maintains a direct position of 603,621 shares. This represents 98% of the executive's prior direct holdings, indicating a modest adjustment to the total investment. - What is the regulatory context for the timing of this sale?
The transaction was scheduled via a Rule 10b5-1 trading plan adopted in January 2025. These plans allow corporate insiders to diversify their portfolios through pre-planned trades, mitigating concerns regarding the use of non-public material information. - What is the company's current development focus?
Mineralys Therapeutics is currently advancing lorundrostat, an investigational aldosterone synthase inhibitor, through clinical trials as a potential treatment for uncontrolled hypertension and associated cardiovascular complications. - How has the stock performed leading up to this transaction?
The company's shares yielded a 90% return over the 12-month period ending on the July 13, 2026 transaction date, with the firm maintaining a market capitalization of $2 billion as of the July 14, 2026 market close.
Company Overview
| Metric | Value |
|---|---|
| Share Price (as of market close 2026-07-14) | $27.28 |
| Market Capitalization | $2 billion |
| Net Income (TTM) | -$151.8 million |
| One Year Total Return | 90% |
Company Snapshot
- Mineralys Therapeutics is a clinical-stage biopharmaceutical company developing innovative treatments for hypertension and cardiovascular disease, with lorundrostat, an orally administered aldosterone synthase inhibitor, as its primary investigational asset.
- The company operates under a development-stage business model focused on advancing proprietary drug candidates through clinical trials with the objective of achieving regulatory approval and commercialization in the cardiovascular therapeutic space.
- Mineralys targets patients with difficult-to-treat, uncontrolled hypertension and related cardiovascular complications, positioning its therapies for the substantial patient population requiring improved treatment options.
Mineralys Therapeutics is a clinical-stage biopharmaceutical company with a market capitalization of $2 billion, currently advancing investigational therapies for cardiovascular disease management. The company operates with a lean operational footprint while maintaining focus on its lead candidate, lorundrostat, which addresses an underserved patient population with resistant hypertension. As a pre-revenue clinical entity, Mineralys is positioned within the high-risk, high-reward segment of the biotechnology sector, with value creation contingent upon successful clinical development and regulatory approval of its pipeline assets.
What this transaction means for investors
When a chief executive parts with about 2% of his stock on a schedule locked in more than a year earlier, especially with shares up 90% over the past year, this really just seems like a diversification or financial planning move.
More important is what’s on the horizon for Mineralys, which has an FDA decision date of December 22 for lorundrostat, its blood-pressure drug, after the agency accepted the filing backed by two pivotal trials showing meaningful, durable reductions. The company is pre-revenue and burning cash, posting a $39.3 million loss for the quarter ending March 31, but its $646.1 million cash pile funds operations into 2028 (before a $150 million offering in June), well past that decision. Congleton called the FDA acceptance a "significant milestone." And that’s why, ultimately, the sale here is noise. Instead, the December 22 approval decision, plus whether Mineralys launches alone or with a partner, is what actually decides the stock.
Jonathan Ponciano has no position in any of the stocks mentioned. The Motley Fool recommends Mineralys Therapeutics. The Motley Fool has a disclosure policy.